Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.61 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430824 | 1.00 | CES2 (0.61) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL14976704 | 1.00 | CES2 (0.61) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL2442645 | 1.00 | CES2 (0.61) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL2440945 | 1.00 | CES2 (0.61) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL2444713 | 1.00 | CES2 (0.61) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL14976297 | 1.00 | CES2 (0.61) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL7307622 | 0.89 | CES2 (0.55) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL15710411 | 0.88 | TERT (0.61) | PPARGPPARDPPARATDP1MEN1 | |
| SCHEMBL15809511 | 0.84 | CES2 (0.59) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL20446673 | 0.84 | CES2 (0.59) | CES2CES1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4166128-A1 | LEAVE-IN HAIR CARE EMULSION | Henkel AG & Co. KGaA (DE) | 2023-04-19 | — | — | EP | claimed |
| EP-2782644-A2 | HAIR-CONDITIONING AGENTS | Henkel AG & Co. KGaA (DE) | 2014-10-01 | — | — | EP | claimed |
| US-20140246041-A1 | HAIR-CONDITIONING AGENTS | HENKEL AG & CO. KGAA (DE) | 2014-09-04 | — | — | US | claimed |
| WO-2013075892-A2 | HAIR-CONDITIONING AGENTS | HENKEL AG & CO. KGAA (DE) | 2013-05-30 | — | — | WO | claimed |
| WO-2024136610-A1 | COMPOSITION COMPRISING PH-SENSITIVE LIPID NANOPARTICLES CONTAINING CATIONIC MATERIAL | 동아제약 주식회사 | 2024-06-27 | — | — | WO | disclosed |
| US-12016944-B2 | Mixtures comprising a protein extract for the treatment of human skin and/or hair | SYMRISE AG (DE) | 2024-06-25 | — | — | US | disclosed |
| US-20240156704-A1 | FORMULATION COMPRISING ESTER QUATS BASED ON TRIALKANOLAMINES | EVONIK OPERATIONS GMBH (DE) | 2024-05-16 | — | — | US | disclosed |
| EP-4360617-A1 | FORMULATION COMPRISING ESTER QUATS BASED ON TRIALKANOLAMINES | Evonik Operations GmbH (DE) | 2024-05-01 | — | — | EP | disclosed |
| US-20240130957-A1 | EXTRACTS OF ISOCHRYSIS SPECIES/TISOCHRYSIS SPECIES | SYMRISE AG (DE) | 2024-04-25 | — | — | US | disclosed |
| US-20240122831-A1 | AQUEOUS COMPOSITIONS COMPRISING 6-UNDECANOL-ESTERS | EVONIK OPERATIONS GMBH (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20240082138-A1 | ACIDIC GLUCOSE-BASED HAIR CARE COMPOSITION | CHAMBERS JR PAUL R (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240075089-A1 | BOTANICALS AS WNT/BETA-CATENIN ACTIVATORS, MOLECULAR PATHWAY REGULATORS, TISSUE REGENERATORS AND HEALTH BIOMARKER REGULATORS | ARBOR LIFE HOLDINGS, LTD. (CA) | 2024-03-07 | — | — | US | disclosed |
| WO-2004026271-A1 | COMPOSITIONS OF ANIONIC POLYMERIC RHEOLOGY MODIFIERS AND CATIONIC MATERIALS | NOVEON IP HOLDINGS CORP. (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040052748-A1 | Compositions of anionic polymeric rheology modifiers and cationic materials | LUBRIZOL ADVANCED MATERIALS, INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1303260-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | Pericor Science, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1203141-A1 | LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202706-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002007707-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | PERICOR SCIENCE, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140246041-A1 | HAIR-CONDITIONING AGENTS | KRT18, OAT, HGF | CES2 780/4885CES1 2949/4885PPARG 455/4885 |
| US-20240156704-A1 | FORMULATION COMPRISING ESTER QUATS BASED ON TRIALKANOLAMINES | SQLE, KHK, CUTA | CES2 228/4885CES1 139/4885PPARG 146/4885 |
| US-20040052748-A1 | Compositions of anionic polymeric rheology modifiers and cationic materials | PBRM1, PARG, PARN | CES2 4425/4885CES1 4515/4885PPARG 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.